1. Immunoglobulin therapies are absolutely essential, lifelong treatments for the majority of people with primary immunodeficiency (PID) and are used to treat some people affected by secondary antibody deficiency.
  2. The administration of life-saving immunoglobulin therapies derived from human plasma provides antibodies which are protective against a broad range of infections.
  3. Immunoglobulin therapies are included in the World Health Organisation (WHO) Lists of Essential Medicines. All countries should provide access to the broadest spectrum of immunoglobulin therapies possible.
  4. There is no alternative therapy for most primary immunodeficiency diseases and immunoglobulin therapies should be prioritised for people who need it most.
  5. Those people needing immunoglobulin therapy rely on the generosity and commitment of plasma and blood donors. Plasma donations are an essential gift to people in need of immunoglobulins and other plasma-derived medicinal products.
  6. Different modes of administration exist (intravenous immunoglobulin IVIG and subcutaneous immunoglobulin), and no single immunoglobulin therapy or delivery method is suitable for all individuals. It is crucial to ensure optimal treatment is provided to people on an individualised basis, tailored to their personal needs.

Updated August 2022